| First Author | Kim MY | Year | 2023 |
| Journal | Exp Mol Med | Volume | 55 |
| Issue | 10 | Pages | 2177-2189 |
| PubMed ID | 37779138 | Mgi Jnum | J:342256 |
| Mgi Id | MGI:7545949 | Doi | 10.1038/s12276-023-01073-2 |
| Citation | Kim MY, et al. (2023) Trametinib activates endogenous neurogenesis and recovers neuropathology in a model of Alzheimer's disease. Exp Mol Med 55(10):2177-2189 |
| abstractText | Enhancing adult neurogenesis in the brain has been suggested as a potential therapeutic strategy for AD. We developed a screening platform, ATRIVIEW((R)), for molecules that activate neuronal differentiation of adult mouse NSCs. The most potent hit from an FDA-approved drug library was SNR1611 (trametinib), a selective MEK1/2 inhibitor. We found that trametinib increases the levels of P15(INK4b) and Neurog2, suggesting a mechanism by which MEK1/2 inhibition induces neuronal differentiation. Oral administration of trametinib increased adult neurogenesis in the dentate gyrus and subventricular zone of the 5XFAD AD mouse model. Surprisingly, we also found that trametinib enhanced adult neurogenesis in the cortex. Consequently, trametinib rescued AD pathologies such as neuronal loss and cognitive impairment in 5XFAD mice. Finally, trametinib induced neurogenic differentiation of NSCs derived from AD patient iPSCs, which suggests its potential therapeutic application. Altogether, we suggest that restoration of endogenous adult neurogenesis by trametinib may be a promising therapeutic approach to AD. |
